“…Thus, a few drugs for AD have been approved by the US Food and Drug Administration (FDA), including donepezil, rivastigmine, and galantamine (cholinesterase inhibitors), memantine (an N-methyl-D-aspartate receptor partial antagonist), and a combination of donepezil and memantine. All these drugs, however, have limited effectiveness and they do not reverse the progression of the disease or improve cognitive dysfunction, but they rather delay the deterioration of AD symptoms for a limited time period [8]. Recently, a fully human monoclonal antibody targeting Aβ, aducanumab, has been approved by the FDA, although there has been some controversy concerning the overall efficacy of this passive immunotherapeutic agent [20][21][22][23][24].…”